Alebund – 第2页

Alebund Pharmaceuticals and Peking University First Hospital enter into a strategic partnership to develop a novel and specific treatment for IgA Nephropathy (IgAN)

Posted on 2022-06-302022-06-30 by Alebund

SHANGHAI/BEIJING, CHINA, June 30, 2022 — Alebund Pharmaceuticals, a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced a strategic partnership between its subsidiary Alezyme and Peking University First Hospital, to discover, develop and commercialize PKU308/AP308, a potential innovative and specific therapeutic for IgAN. Designed and developed by Peking University First Hospital, this compound has a completely innovative mechanism of action (MOA) as compared to currently available treatment options.

Alebund Pharmaceuticals Holds Groundbreaking Ceremony for Yangzhou Research and Production Base

Posted on 2021-12-072022-06-02 by Alebund

Yangzhou, China, Dec. 7, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, held today a groundbreaking ceremony for its research and production plant in Jiangsu province’s Yangzhou city.

Alebund Pharmaceuticals Raises $54.5 Million in Series B+ Financing Round to Fuel Development of Renal Disease Treatment

Posted on 2021-09-142021-09-13 by Alebund

Shanghai, China, Sep. 14, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has secured $54.5 million in its Series B+ financing round. This round was led by 3H Health Investment, Loyal Valley Capital and Morningside Ventures, followed by YuanBio Venture Capital, Octagon Capital, Verition Fund Management and HT Capital. Existing Shareholders including Lilly Asia Ventures, Quan Capital, a prominent sovereign wealth fund, 3E Bioventures Capital and Sherpa Healthcare Partners also took part in the financing. Proceeds raised in this round will help accelerate the development of Alebund’s clinical programs, the construction of the manufacturing site, the research of pre-clinical assets, and the expansion of Company’s talent pool.

Chugai and Alebund Enter into Option and License Agreement for EOS789 under Development for Hyperphosphatemia

Posted on 2021-07-092021-07-09 by Alebund

Chugai Pharmaceutical Co., Ltd.
Alebund Pharmaceuticals (Hong Kong) Limited

Chugai and Alebund enter into an option and license agreement regarding EOS789, an investigational drug for hyperphosphatemia, discovered by Chugai
If Alebund decides to exercise the option, Chugai will grant to Alebund an exclusive license to develop, manufacture, and commercialize EOS789 worldwide including Japan

TOKYO, JAPAN and SHANGHAI, CHINA, July 9, 2021 — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Alebund Pharmaceuticals (Hong Kong) Limited, announced that they have entered into an option and license agreement regarding Chugai’s EOS789, an investigational agent under development for hyperphosphatemia.

Alebund Pharmaceuticals Raises $60 million in Series B Financing Round to Accelerate Its Development of Innovative Drugs and Total Solutions for the Treatment of Renal Diseases

Posted on 2021-05-102021-05-10 by Alebund

Shanghai, China. May 10, 2021 – Alebund Pharmaceuticals (“Alebund” or the “Company”), a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions, today announced that it has raised $60 million in its Series B financing round which was led by Quan Capital, and followed by a prominent sovereign wealth fund, 3E Bioventures Capital, and Sherpa Healthcare Partners. Existing Shareholders, Lilly Asia Ventures and Med-Fine Capital, also took part in this financing round. Proceeds raised from this round will be invested in the research and development of pre-clinical assets, clinical programs, the construction of the manufacturing site, and the expansion of Company’s talent pool.

Author: Alebund